Company Profiles

driven by the PitchBook Platform

Gem Pharmaceuticals

Description

Developer of anthracycline derivatives designed to eliminate the critical cardiotoxicity side effect of this powerful class of chemotherapeutics while maintaining their well-documented anti-cancer efficacy. The company's anthracycline derivatives effectively transform traditional broad-spectrum cytotoxic drugs into modern -- and biochemically targeted -- anti-cancer agents that hold the potential for higher cumulative dosing and previously problematic drug combinations, thereby enabling doctors to correspondingly improve therapeutic utility. The company's non-cardiotoxic doxorubicin analogue, GPX-150, has completed a successful Phase 2 study in sarcoma, where Gem has obtained orphan drug designation.

2001

Founded

PRIVATE

Status

11-50

Employees

Later Stage VC

Latest Deal Type

$4.5M

Latest Deal Amount

$15M

Total Amount Raised

Description

Developer of anthracycline derivatives designed to eliminate the critical cardiotoxicity side effect of this powerful class of chemotherapeutics while maintaining their well-documented anti-cancer efficacy. The company's anthracycline derivatives effectively transform traditional broad-spectrum cytotoxic drugs into modern -- and biochemically targeted -- anti-cancer agents that hold the potential for higher cumulative dosing and previously problematic drug combinations, thereby enabling doctors to correspondingly improve therapeutic utility. The company's non-cardiotoxic doxorubicin analogue, GPX-150, has completed a successful Phase 2 study in sarcoma, where Gem has obtained orphan drug designation.

Website:

www.gempharmaceuticals.com

Ownership Status

Privately Held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Discovery

Primary Office

941 Lake Forest Circle Birmingham, AL 35244United States +1 (205) 982-8383
    Request a free trial to the PitchBook Platform
    You're viewing a free company profile from the PitchBook Platform. To explore Gem Pharmaceuticals's full profile, request a free trial.

    Gem Pharmaceuticals Valuation and Funding

    Request access
    Deal TypeDateAmountRaised to DatePost-ValStatusStage

    Gem Pharmaceuticals Investors (3)

    Request access
    Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
    Seat
    Contact
    Info
    Hendricks Holding CompanyHolding CompanyMinority000 0000000 0000
    Individual InvestorAngel (individual)Minority000 0000000 0000
    Karl LeoAngel (individual)000 0000000 0000
    Hendricks Holding Company Holding Company
    Individual Investor Angel (individual)
    Karl Leo Angel (individual)

    Gem Pharmaceuticals Executive Team (7)

    NameTitleBoard
    Seat
    Contact
    Info
    Arthur KlausnerChief Executive Officer & Board Member
    Richard Olson Ph.DCo-Founder, Chief Science Officer, Chairman Medical Advisory Board & Board Member
    Barry CusackAdvisor
    Gloria Lee MDAdvisor
    Robert Maki Ph.DAdvisor
    Arthur Klausner Chief Executive Officer & Board Member
    Richard Olson Ph.D Co-Founder, Chief Science Officer, Chairman Medical Advisory Board & Board Member
    Barry Cusack Advisor
    Gloria Lee MD Advisor
    Robert Maki Ph.D Advisor

    Gem Pharmaceuticals Board Members (6)

    NameRepresentingRoleSinceContact
    Info
    Arthur KlausnerGem PharmaceuticalsChief Executive Officer & Board Member000 0000
    Diane HendricksHendricks Holding CompanyCo-Founder & Chairman000 0000
    Donald Drakeman Ph.DSelfBoard Member000 0000
    Gerald Walsh JDSelfCo-Founder, President, Chief Operating Officer & Board Member000 0000
    Karl Leo JDSelfChairman000 0000
    Arthur Klausner Chief Executive Officer & Board Member Gem Pharmaceuticals
    Diane Hendricks Co-Founder & Chairman Hendricks Holding Company
    Donald Drakeman Ph.D Board Member Self
    Gerald Walsh JD Co-Founder, President, Chief Operating Officer & Board Member Self
    Karl Leo JD Chairman Self
    Request full access to PitchBook